WK2
WK2 is an antibacterial agent. WK2 reduces serum TNF-α production induced by Bacterial infection. WK2 reduces wound size and promotes tissue repair in a skin wound infection model. WK2 exerts anti-inflammatory effects in a pneumonia model. WK2 can be used for research on infectious diseases such as pneumonia caused by bacterial infection.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Fòrmula: C76H105N19O10
- Peso molecular:1444.77
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas TNF Receptor
More
Actividad biológica
Descripciòn
In Vitro
In Vivo
WK2 (2 mg/kg; topical administration; via 10 μL saline drops; 6-36 h post-infection) exhibits antibacterial activity in a mouse skin wound model infected with MRSA, reduces bacterial load, and promotes complete wound healing as well as regeneration of normal skin structure[2].
WK2 (15 mg/kg; i.p.; 30 min post-LPS injection) exhibits selective anti-inflammatory activity in a mouse model of LPS-induced systemic inflammation and reduces plasma TNF-α levels[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c mice (male, 6-8 weeks old, 18-20 g, intratracheal Klebsiella pneumoniae infection (50μL, 1×109 CFU/mL))[2]
-
Dosage:5 mg/kg
-
Administration:i.p.; at 6, 12, 24, 30, and 36 h post-infection
-
Result:Reduced lung Klebsiella pneumoniae counts to 4.1 × 105 CFU/mg, compared to 2.67 × 106 CFU/mg in untreated infected mice.\nAlleviated inflammatory cell infiltration and promoted alveolar expansion, with less inflammation.
-
Animal Model:BALB/c mice (male, 6-8 weeks old, 18-20 g, dorsal wound methicillin-resistant Staphylococcus aureus infection (10 μL, 1 × 107 CFU/mL) )[2]
-
Dosage:2 mg/kg
-
Administration:topical; via 10 μL saline drops; at 6, 12, 24, 30, and 36 h post-infection
-
Result:Exhibited significant antibacterial activity.
Demonstrated significant anti-MRSA activity, effectively preventing wound ulceration, gradually promoting wound healing, and causing the wound area to gradually decrease over time.
Improved the pathological changes in MRSA-infected mice, including wound thickening, inflammatory cell infiltration, and reduction of sebaceous glands and hair follicles.
-
Animal Model:BALB/c mice (male, 6-8 weeks old, 18-20 g, LPS (10 mg/kg,) i.p.)[2]
-
Dosage:15 mg/kg
-
Administration:i.p.; 30 min post-LPS injection
-
Result:Reduced TNF-α levels induced by LPS.
Chemical Information
-
Peso molecular 1444.77
-
Fòrmula C76H105N19O10
-
Sequence
Gly-Trp-Trp-Lys-Lys-Trp-Trp-Lys-Lys-Ile-NH2
-
Sequence Shortening
GWWKKWWKKI-NH2
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. Ouyang X, et al. Fluorinated Modification as a Simple Strategy That Effectively Enhances the Stability and Activity of Antimicrobial Peptides. J Med Chem. 2025;68(19):20081-20102. [Content Brief]
[2]. Ouyang X, et al. High Therapeutic Index α-Helical AMPs and Their Therapeutic Potential on Bacterial Lung and Skin Wound Infections. ACS Infect Dis. 2024;10(9):3138-3157. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
WK2 Related Classifications
HY-P11616 Related Classifications
Powered by Bioz